Pourtier-Manzanedo A - Search Results

1

Dominant-negative inhibition of Ets 1 suppresses tumor growth, invasion and migration in rat C6 glioma cells and reveals differentially expressed Ets 1 target genes.

Sahin A, Vercamer C, Kaminski A, Fuchs T, Florin A, Hahne JC, Mattot V, Pourtier-Manzanedo A, Pietsch T, Fafeur V, Wernert N. Sahin A, et al. Among authors: pourtier manzanedo a. Int J Oncol. 2009 Feb;34(2):377-89. Int J Oncol. 2009. PMID: 19148472

2

Expression of an Ets-1 dominant-negative mutant perturbs normal and tumor angiogenesis in a mouse ear model.

Pourtier-Manzanedo A, Vercamer C, Van Belle E, Mattot V, Mouquet F, Vandenbunder B. Pourtier-Manzanedo A, et al. Oncogene. 2003 Mar 27;22(12):1795-806. doi: 10.1038/sj.onc.1206215. Oncogene. 2003. PMID: 12660815

3

[Experimental angiogenesis : strategy for the functional study of the transcription factors of the Ets family during morphogenesis of the vascular tree].

Mattot V, Pourtier-Manzanedo A, Vercamer C, Soncin F, Vandenbunder B. Mattot V, et al. Among authors: pourtier manzanedo a. Ann Endocrinol (Paris). 2000 Feb;61(1):61-9. Ann Endocrinol (Paris). 2000. PMID: 10790594 Review. French.

4

Expression of P-glycoprotein on normal lymphocytes: enhancement of the doxorubicin-sensitivity of concanavalin A-responding mouse spleen cells by P-glycoprotein blockers.

Pourtier-Manzanedo A, Didier A, Loor F. Pourtier-Manzanedo A, et al. Oncol Res. 1992;4(11-12):473-80. Oncol Res. 1992. PMID: 1363723

5

FK-506 (fujimycin) reverses the multidrug resistance of tumor cells in vitro.

Pourtier-Manzanedo A, Boesch D, Loor F. Pourtier-Manzanedo A, et al. Anticancer Drugs. 1991 Jun;2(3):279-83. doi: 10.1097/00001813-199106000-00010. Anticancer Drugs. 1991. PMID: 1724925

6

Lymphotoxicity and myelotoxicity of doxorubicin and SDZ PSC 833 combined chemotherapies for normal mice.

Pourtier-Manzanedo A, Didier A, Froidevaux S, Loor F. Pourtier-Manzanedo A, et al. Toxicology. 1995 May 23;99(3):207-17. doi: 10.1016/0300-483x(95)03056-l. Toxicology. 1995. PMID: 7610467

7

SDZ PSC 833 and SDZ 280-446 are the most active of various resistance-modifying agents in restoring rhodamine-123 retention within multidrug resistant P388 cells.

Pourtier-Manzanedo A, Didier AD, Muller CD, Loor F. Pourtier-Manzanedo A, et al. Anticancer Drugs. 1992 Aug;3(4):419-25. doi: 10.1097/00001813-199208000-00017. Anticancer Drugs. 1992. PMID: 1421439

8

In vivo circumvention of P-glycoprotein-mediated multidrug resistance of tumor cells with SDZ PSC 833.

Boesch D, Gavériaux C, Jachez B, Pourtier-Manzanedo A, Bollinger P, Loor F. Boesch D, et al. Cancer Res. 1991 Aug 15;51(16):4226-33. Cancer Res. 1991. PMID: 1678313

9

SDZ 280-446, a novel semi-synthetic cyclopeptolide: in vitro and in vivo circumvention of the P-glycoprotein-mediated tumour cell multidrug resistance.

Loor F, Boesch D, Gavériaux C, Jachez B, Pourtier-Manzanedo A, Emmer G. Loor F, et al. Among authors: pourtier manzanedo a. Br J Cancer. 1992 Jan;65(1):11-8. doi: 10.1038/bjc.1992.3. Br J Cancer. 1992. PMID: 1346365 Free PMC article.

10

Restoration of daunomycin retention in multidrug-resistant P388 cells by submicromolar concentrations of SDZ PSC 833, a nonimmunosuppressive cyclosporin derivative.

Boesch D, Muller K, Pourtier-Manzanedo A, Loor F. Boesch D, et al. Among authors: pourtier manzanedo a. Exp Cell Res. 1991 Sep;196(1):26-32. doi: 10.1016/0014-4827(91)90452-z. Exp Cell Res. 1991. PMID: 1879470

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

12 results

Search Page

Filters